Optivise Advisory Services’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.24M Buy
1,869
+68
+4% +$69.5K 1.14% 18
2026
Q1
$1.66M Sell
1,801
-62
-3% -$62.9K 1% 23
2025
Q4
$2M Buy
1,863
+108
+6% +$103K 1.15% 17
2025
Q3
$1.34M Sell
1,755
-165
-9% -$123K 0.8% 35
2025
Q2
$1.5M Sell
1,920
-103
-5% -$80K 0.76% 32
2025
Q1
$1.67M Buy
2,023
+32
+2% +$26.6K 0.94% 21
2024
Q4
$1.54M Buy
1,991
+37
+2% +$30.6K 0.83% 32
2024
Q3
$1.73M Buy
1,954
+31
+2% +$27.9K 0.91% 27
2024
Q2
$1.74M Buy
+1,923
New +$1.54M 0.94% 27

Other funds holding LLY

Optivise Advisory Services's LLY Position: Q2 2026 in Review

Optivise Advisory Services increased its Eli Lilly (LLY) stake by 3.8% in Q2 2026, buying an estimated $69.5K and bringing the position to 1,869 shares worth $2.24M. The position accounts for 1.14% of the portfolio, ranked #18.

Optivise Advisory Services first reported a position in LLY in Q2 2024 and has held it in 9 quarters since. 1,578 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Optivise Advisory Services held 1,869 shares of Eli Lilly worth $2.24M as of Q2 2026.
  • Optivise Advisory Services bought 68 Eli Lilly shares in Q2 2026, an estimated $69.5K.
  • Eli Lilly made up 1.14% of Optivise Advisory Services's portfolio in Q2 2026, its #18 holding.
  • Optivise Advisory Services first reported a position in Eli Lilly in Q2 2024 and has held it in 9 quarters since.
  • 1,578 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Optivise Advisory Services's 13F filing for Q2 2026, filed 13 Jul 2026.